Bylvay may not be effective in PFIC type 2 patients with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3).
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A05 BILE AND LIVER THERAPY
A05A BILE THERAPY
A05AX Other drugs for bile therapy
A05AX05 Odevixibat
D13092 Odevixibat hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Odevixibat
D13092 Odevixibat hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
391 Liver disease agents
3919 Others
D13092 Odevixibat hydrate (JAN)
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03339 Odevixibat
D13092 Odevixibat hydrate
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC10
SLC10A2 (ASBT, IBAT)
D13092 Odevixibat hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D13092
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D13092
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D13092
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D13092
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D13092
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D13092
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03339 Odevixibat